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INTRODUCTION 
In this time, a major goal for the drug delivery research is 
turned towards the development of efficacious drug delivery 
systems with already existing active ingredients incase of 
new drug discovery1. Many of pharmaceutical therapeutic 
agents are mostly effective when made available at constant 
rates or near to absorption sites. Much effort has been going 
on to develop sophisticated drug delivery systems such as 
osmotic devices for oral application. Oral drug delivery 
system is more favored on popular controlled drug delivery 
system in pharmaceutical research and development (R & D) 
business due to increase in awareness of medical and 
pharmaceutical community, about the importance of safe and 
effective use of drug. This system aims to maintain plasma 
drug concentration within the therapeutic window for long 
period of time
2
. Traditionally, it is becoming increasingly 
more evident with the specific time that patients have to take  
 
their medication may be even more significant than was 
recognized in the past. The tradition of prescribing 
medication at evenly spaced time intervals throughout the 
day, in an attempt to maintain constant drug levels 
throughout a 24-hour period, may be changing as 
researcher’s report that some medications may work better if 
their administration is coordinated with day-night patterns 
and biological rhythms. In the human body systems such as 
cardiovascular, pulmonary, hepatic and renal systems show 
variation in their function throughout a typical day. They are 
naturally followed by the internal body clocks and are 
controlled by the sleep wake cycle. This system focused on 
controlled or sustained release of drug of which has such 
advantages of nearly constant level of drug at site of 
administration, minimizing peak – valley fluctuation of drug 
concentration in body and avoidance of adverse effect. A 
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reduction in dose, dosage frequency, patient efficacy and 
compliance by this delivery system can also expected3. 
However, a release pattern of drug is not suitable in certain 
disease condition. At that time release profile of a delivery 
system was characterized by lag time. In other words, the 
drug should not release during its initial period of 
administration, followed by a rapid and complete release 
(pulse release) of drug that is called pulsatile drug delivery 
system4. This system aims to deliver a drug via the oral route 
at a rate different than constant i.e., zero order release5-10. 
The lag time is the time interval between the dosage forms is 
placed into the aqueous environment and drug get to release 
from its dosage form after rupturing or eroding outer layer. 
The lag time between 0.5 to 4 hours is desire for upper 
region of gastrointestinal tract and more than 4 hours for 
lower portion of small intestine11. "Chronopharmaceutics" 
consist of two words chronobiology and pharmaceutics. 
Chronobiology is the study of biological rhythms and their 
mechanisms. Mainly mechanical rhythms in our body are:  
 Circadian - this word comes from Latin word 
"circa" means about and "dies" means day and oscillation 
completed in 24 hours 
 Ultradian - oscillation of shorter duration(more than 
one cycle per 24 h)  
 Infradian - oscillations that are longer than 24 h 
(less than one cycle per day)  
Circadian rhythms are self-sustaining, endogenous 
oscillations that occur with a periodicity of about 24 hours 
and regulate many body functions like– metabolism, sleep 
pattern, hormone production etc. PDDS are widely important 
in such wide spread disease which is mentioned in Table-1.  
Table 1: Circadian rhythm and the manifestation of clinical diseases 
SL.No Cardiac rhythmicity Disease or syndrome 
1 
Exacerbation more common during the sleep period & attacks after 
midnight or at early morning hours 
Asthma 
2 Worse in the morning/upon rising Allergic Rhinitis 
3 
Growth hormone and melatonin produced at night; testosterone and 
cortisol in morning hr 
Hormone Secretion 
4 
Even with constant heparin infusion rate, thromboplastin time and risk 
of bleeding vary significantly during the day 
Blood Coagulation 
5 Morning pain and more in night Rheumatoid Arthritis 
6 Symptoms worse in the middle/later portion of the day Osteoarthritis 
7 Chest pain and ECG changes more common in early morning Angina Pectoris 
8 Increased blood sugar level after meal Diabetes mellitus 
9 Incidence higher in the early morning Myocardial Infraction 
10 Incidence higher in the morning Stroke 
11 Cholesterol synthesis is generally higher during night than day time Hypercholesterolemia 
12 Incidence higher in the morning after awakening Sudden cardiac death 
13 Acid secretion high in afternoon and at night Peptic ulcer disease 
14 Increase Dopa level in afternoon Attention deficit syndrome 
 
The lag time is essential for those drugs that undergo 
degradation in gastric acidic medium like- peptide drugs, 
irritate the gastric mucosa or which induce nausea and 
vomiting. Like these conditions enteric coating providing 
satisfactory results12 and also enteric coating can be 
considered as a pulsatile drug delivery system. 
The comparison between conventional sustained release and 
pulsatile drug delivery system is shown in Figure 1 and 
sustained release approach which shift to modern pulsatile 
drug delivery having certain advantages: 
 Chronopharmacotherapy of diseases which shows 
circadian rhythms in their pathophysiology 
 Extended day time or night time activity 
 
 
 Avoiding the first pass metabolism e.g., protein and 
peptides
13
  
 Biological tolerance (e.g., transdermal nitroglycerin) 
 For targetting specific site in intestine e.g., colon 
 For time programmed administration of hormone and 
drugs  
 Gastric irritation or drug instability in gastric fluid 
 For drugs having the short half life  
 Lower daily cost to patient due to fewer dosage units are 
required in therapy 
 Reduction in dose size and dosage frequency and also 
side effects 
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Sustained release system Pulse release system
 
Figure 1: A comparison between sustained and pulsatile release system 
PDDS increases its attention in treatment of peak symptoms in early morning and exhibit circardian rhythm. The first pulsed 
delivery formulation that released the active substance at a precisely defined time point was developed in the early 1990s. The 
different drug used for chronotherapies are shown in Table 2. 
Table 2: Drugs developed or under development as chronotherapies 
SL.NO Class Examples of drugs 
1 Cardiovascular Drugs Verapamil, Felodipine, Propranolol, Captopril, Metoprolol, Diltiazem, 
Nifedipine, Enalapril, Nitrogycerine, Dofetilide. 
2 Antiasthmatic Drugs Methylprednisolone, Prednisolone, Albuterol, Terbutaline, Theophylline, 
Montelukast sodium, Budesonide 
3 Anticancer Drugs Cisplatine, Oxaliplatine, Doxorubicin, 5- fluorouracil, Folinic acid, 
Methotrexate, Mercaptopurine 
4 NSAIDs Diclofenac sodium, Ibuprofen, ketoprofen, oxymorphone, Indomethacine, 
Tenoxicam, Acetylsalicylic acid, 
5 Diabetes Mellitus Sulphonylurea, insulin 
6 Anti Angina Drug Nitroglycerine 
7 Anti Ulcer Drugs Cimetidine, Ranitidine, Famotidine, Pirenzipine, Omeprazole 
8 Anti Cholesterolemic 
Drugs 
Simvastatin, Lovastatin 
9 In Irritable Bowel Disease 5-amino salicylic acid 
10 Others Amoxycilline, Vitamin D3, Dizepam, Haloperidol, Methylphenidate, 
 
CLASSIFICATION OF PDDS 
A. PRE-PROGRAMMED DELIVERY SYSTEM 
1. Time controlled pulsatile drug delivery system 
Principally, timed pulsatile delivery system is capable of 
providing one or more rapid release pulses at predetermined 
lag times or at specific sites, results in better absorption with 
effective plasma concentration-time profile for a therapeutic 
agent. Due to potential limitations of the dosage form size, 
and/or polymeric materials and their compositions, a few 
orally applicable pulsatile release systems are going for 
approach. 
a. Capsular structure based system 
The pharmaceutical capsular dosage form that releases its 
drug content at either a predetermined time or at a specific 
site (e.g., colon) in the gastrointestinal tract e.g., 
PULSINCAP14,15. The drug formulation consists of insoluble 
capsular body, swellable and degradable plugs which made 
up of approved substances such as hydrophilic polymers, 
lipids and bioactive molecules. After oral administration this 
capsular system came in contact with the gastrointestinal 
fluid than hydrogel plug swells and at preprogrammed lag 
time period, the plug pushes out side and rapid release the 
drugs. Generally to develop plug, polymeric substances used 
such as poly vinyl acetate, polyethylene-oxide, hydroxyl 
propyl cellulose etc. This delivery system has also be 
simplify by using erodible tablet in place of hydrogel plug. 
This erodible tablet is completely fit in a capsule to retard the 
fluid entry. Top of capsule dissolve than this tablet erodes 
during release of drug from mouth of capsule. 
b. System based on rupturable coating 
This is a reservoir-type time-controlled pulsatile release 
system consists of water insoluble but water permeable 
polymeric barrier which surrounded to the drug core subject. 
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This drug core is formulated by using osmotic agents or 
swelling or gas producing effervescent additives. So that 
from the dosage form the drug is released from a core after 
the rupture of a surrounding polymer layer because of a 
hydrostatic pressure build-up within the system when it 
immersed into the release media. The pressure necessary to 
rupture the coating can be achieved with gas-producing 
effervescent excipients, inner osmotic pressure or swelling 
agents16. 
A time dependent pulsed release system of salbutamol sulfate 
in nocturnal asthma consisting of an effervescent core 
surrounded by consecutive layers of swelling and rupturable 
polymers was prepared and evaluated. This system prepared 
by direct compression method using different ratios of 
microcrystalline cellulose and effervescent agent and then 
coated sequentially with an inner swelling layer containing a 
hydrocolloid, hydroxypropyl methylcellulose E5 and an 
outer rupturable layer having Eudragit RL / RS (1:1)17. 
c. System based on solubilization or erodible membrane 
 These chronotropic drug delivery systems based on a drug 
reservoir devices coated with a soluble or erodible barrier. 
This barrier erodes or dissolves after and the drug is 
subsequently released rapidly from reservoir core after the 
specific preset time period that depends on the thickness of 
the coating layer. In such systems the drug release is 
controlled by the dissolution or erosion of the outer coat 
which is applied on the core containing drug18. 
Kanakal, et al., prepared theophylline osmotic tablets for 
effect of coating solvent ratio on the drug release lag time. 
This tablets were formulated by direct compression and 
coated by spraying with different ratio of water-alcohol 
containing hydroxy propyl methyl cellulose (HPMC,5cps) as 
primary swelling layer and Eudragit RSPO and RLPO as 
porous layer. The viscosity of the coating solution was 
determined by using Brookfield viscometer. The optimum 
water/alcohol ratio (60:40) as coating solvent produced a 
smooth coated tablet surface texture and modulated drug 
release lag time of tablets19. 
The pulsatile release tablets that can suppress release of the 
drug in the stomach and can release the drug rapidly after a 
predetermined time of about 3 hours in the intestine. The 
system consists of a core, a swelling agent of cross-linked 
PVP and a coating film of ethyl cellulose / Eudragit L. But 
Eudragit L dissolves in an environment of pH above 6 and 
creates pores in the coating film. So Penetration of water 
molecules from the surroundings through the pores into the 
core causes expansion of the swelling agent, bursting the 
film and releasing the drug with a single pulse. Manipulation 
of the thickness of the coating film can control the lag time20. 
d. Osmosis based system 
The principle to activate osmotically chronomodulated 
system for burst release of active ingredients from the 
delivery device must increasing the osmotic pressure inside 
the device that act as driving force. 
In this, the PORT system is to deliver drug as an osmotically 
driven, capsular system was developed called the Port system 
(Figure 2). This system consists of a gelatin capsule coated 
with a outer semi permeable coating membrane (e.g., 
cellulose acetate) housing an insoluble plug (e.g., lipidic) and 
an osmotically active agent along with the drug formulation. 
When this device comes in contact with the aqueous 
environment, water diffuses across the semi permeable 
membrane, resulting in increased inner pressure that ejects 
the plug after a pre-programmed time. The time lag is 
controlled by the thickness of semi permeable membrane. 
The system showed good correlation of in-vitro and in-vivo 
experiments in humans and used in treatment the of 
Attention Deficit Hyper activity Disorder (ADHD) in school 
age children21
 
 
                                 Figure 2: The PORT System (Crison et al., 1996) 
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But in osmotic capsular system, liquid drug is absorbed into 
highly porous particles. In this system the drug is deliver 
through an orifice of a semi permeable capsule supported by 
an expanding osmotic layer after the barrier layer is 
dissolved. The capsular system delivers drug by the capsule's 
osmotic infusion of moisture from the body. The wall of 
capsule created orifice is made up of an elastic material, 
mostly elastomer eg., styrene-butadiene copolymer which 
responsible to stretch the wall under a pressure differential 
caused by pressure rise inside the capsule22.  
2. Site specific pulsatile drug delivery system 
Generally, the aim of site specific and receptor release 
system refers to targeting of the drug directly to a certain 
biological location that means the drug must release at 
targeted site with sufficient amount to maintain peak plasma 
concentration for the desired time period. Environmental 
factors like pH or enzymes present in the intestinal tract and 
also transit time control the release of a site-controlled 
system where as the drug release from time-controlled 
systems is controlled primarily by the delivery system and 
not by the environment. Over the past two decades the major 
challenge for scientist is to target the drugs specially to the 
colonic region of GIT. Previously colon was considered as a 
innocuous organ that responsible for the water absorption, 
electrolytes and stool storage but it’s accepted as important 
site for the delivery of drugs. 
a. pH targeted drug delivery  
Induced targeted drug delivery is a targeting method that 
does not depend on changes in the luminal pH of the GIT, 
but on the pH change within the dosage form itself. Basically 
stomach and small intestine is the part of GIT but significant 
variations in the pH with values ranging from approximately 
1.2 in the stomach to 6.6 in the proximal small intestine and 
a peak of about 7.5 in the distal small intestine followed by a 
sharp decline in colon where the luminal pH is below 723. 
Examples of pH dependent polymers include cellulose 
acetate phthalate, polyacrylates, hydroxypropyl 
methylcellulose phthalates, sodium carboxy methyl cellulose 
etc. are utilized for enteric coating to avoid the degradation 
of drug in upper GIT and attain drug release at specific part 
of intestine (according to solubility of polymer at particular 
pH and specific site of intestine) after a predetermined lag 
time. Theophylline enteric-coated pellets could be 
successfully colon targeted by the design of pH and time-
dependant modified chronopharmaceutical formulation. In 
conclusion, pulsatile drug release over a period of 3-12 hours 
is consistent with the requirements for chronopharmaceutical 
drug delivery. The results of serum study in New Zealand 
rabbits showed that the developed formulation provided a 
significant lag phase of 5 hours24. 
b. Enzymes present in the intestinal tract 
Enzyme controlled drug release relies on the existence of 
enzyme producing microorganism in the colon. The bacterial 
degradable polymers especially azo polymers (the first 
coating materials to be investigated with regard to 
biodegradability in the colon) have been explored in order to 
release an orally administered drug in the colon. Actually 
upon passage of dosage form through the GIT, it remains 
intact in the stomach and small intestine where very little 
microbially degradable activity is present that is quiet 
insufficient for cleavage of polymer coating. The microflora 
of colon is in range of 10
11
-10
12
 CFU / mL and the bacterial 
species in the colon have been estimated to be around 400 
(anaerobic in nature). The colonic microflora produce variety 
of enzymes including β-glucoronidase, β-xylosidase, β-
galactosidase, Igalactosidase, β-arabinosidase, 
nitroreductase, azareductase, deaminase and urea 
dehydroxylase. These enzymes can be exploited for colon 
specific drug delivery. 
c. Transit time / pressure of various part of the 
intestine 
Generally, for achieving site specific targeted delivery 
systems approximately 5 hours are considered sufficient with 
lag times of to target active pharmaceutical ingredints in 
colon. Basically luminal pressure is higher in the pylorus due 
to mechanical stress and to the colon due to reabsorption of 
water. So the pressure controlled colon delivery capsule as 
single unit utilizes the increase in pressure of the luminal 
contents of colon. The drug dispersed in a suppository base 
and coated with ethyl cellulose could take advantage of 
pressure differential in the GI lumen. Temperature of body is 
responsible for suppository base to melt and increases in 
volume which creates balloon of ethyl cellulose that filled 
with liquid. This liquid filled balloon capable to withstand 
small intestinal contractions (peristalsis) but ruptures in the 
colon when subjected to intensive contraction in colon and 
contents of thicker viscosity25. 
B. STIMULUS INDUCED PULSATILE 
DELIVERY SYSTEM 
On the basis of physico-chemical processes in the body this 
novel stimuli induced PDDS is designed at targeted site due 
to physicochemaical stimuli. Examples including release of 
certain enzymes, hormones, antibodies, pH at specific site, 
presence of certain cells, biomolecules like glucose, 
neurotransmitter, inflammatory mediators etc. This 
biologiacal stimuli are responsible to trigger the release of 
drug from the delivery device. 
a. Temperature induced PDDS 
Several polymeric delivery systems undergo phase 
transitions and demonstrate marked swelling-deswelling 
phase in response to temperature which modulate release of 
drug in swollen state such as thermo-responsive hydrogel 
systems26. Bae et al., (1995) developed indomethacin 
pulsatile release pattern in the temperature ranges between 
200 oC and 300 oC by using reversible swelling properties of 
copolymers of N-isopropylacrylamide and 
butyrylacrylamide27. Kataoka et al., (2001) developed the 
thermosensitive polymeric micelles as drug carrier to treat 
the cancer. They used end functionalized poly(N-
isopropylacrylamide) (PIPAAm) to prepare corona of the 
micelle which showed both hydration and dehydration 
behavior with changing temperature28. 
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b. Chemically induced pulsatile drug delivery system 
Mainly classified as follows 
 Glucose responsive insulin release devices 
 Inflammation induced 
Glucose responsive insulin release devices 
Particularly, the development of such delivery systems is 
receiving increasing interest in respond to presence of 
specific enzyme or protein to deliver the active 
pharmaceutical ingredients. Incase of diabetes-mellitus Type-
1, it was depicted earlier that there is rhythmic an increase in 
blood glucose level in body requiring injection of the insulin 
at proper time. The technology has been developed for 
automatically release of insulin in response to change in 
glucose concentration. pH dependent systems for glucose 
sensitive hydrogel sytem based on glucose oxidase enzyme 
which is immobilized in hydrogel. This enzyme is 
responsible for catalyses oxidation of glucose into glucoronic 
acid as the blood concentration of glucose rises which 
changes the pH of system. Due to change in pH, swelling of 
polymer takes place and these results into insulin release. 
Insulin decreases the blood glucose level and consequently 
the gluconic acid level also declines and system turns to 
deswelling and hence decreasing the insulin release. 
Examples of such pH sensitive polymers include n-dimethyl 
amino ethyl methacrylate, chitosan, polyol etc29. Obaidat and 
Park prepared a copolymer of acryl amide and allyl glucose. 
The side chain glucose units in the copolymer were bound to 
concanavalin A. These hydrogels showed a glucose-
responsive, sol–gel phase transition dependent upon the 
external glucose concentration30. 
Inflammation induced pulsatile drug delivery system 
Any physical or chemical stress like-injury, fracture etc. 
which acts as a stimulus in the case of inflammation due to 
hydroxyl radicals produced from inflammation responsive 
cells. Yui et al., (1992), designed and prepared stimuli based 
inflammation responsive chronotropic system which 
responded to hydroxyl radicals and degraded in a limited 
manner. Basically with the system utilized hyaluronic acid 
(HA) which is specifically hydrolyzed by hyaluronidase or 
free radicals that present at inflammatory site. Degradation of 
HA via the hyaluronidase is very low in a normal state of 
health. Hence it became possible to treat patient with 
inflammatory diseases like rheumatoid arthritis, NSAIDS 
incorporated into hyaluronic acid gels as a new implantable 
drug delivery system31. 
c. Externally stimulated pulsatile drug delivery 
systems 
These kinds of open-loop systems are not self-regulated. But 
for deliver the drug in pulse manner another way in which 
drug release in programmed pattern can be the external 
regulated system. These systems are magnetically stimulated, 
ultrasonically modulated and photo stimulated. 
Magnetically stimulated system 
Contain magnetic beads in implant and its approach based on 
magnetic attraction is the slowing down of oral drugs in the 
gastrointestinal system. in this drug release occurs due to 
magnetic beads. Magnetic carriers receive their magnetic 
response to magnetic field such as magnet, iron, nickel, 
cobalt etc. Us patent 2006997863 given one treatment 
method which consists of single domain magnetic particles 
attached  to a target specific ligand for the administration of 
magnetic materials to the patient and the application of an 
alternating magnetic field to inductively heat the magnetic 
material composition that cause the trigger release of active 
agents at the targeted tumour cells. Saslawski et al., 
developed different formulation forin vitro magnetically 
triggered delivery of insulin based on alginate spheres32. 
Ultrasonically modulated system 
It is mostly used as an enhancer for the improvement of drug 
permeation through biological barriers, such as skin, lungs, 
intestinal wall and blood vessels. Ultrasonic waves cause the 
erosion of the polymeric matrix thereby modulating drug 
release. Miyazaki et al., (1998), evaluated the effect of 
ultrasound (1 MHz) on the release rates of bovine insulin 
from ethylenevinyl alcohol copolymer matrices and 
reservoir-type drug delivery systems in which they found 
sharp drop in blood glucose levels after application of 
ultrasonic waves33. 
Photo stimulated system 
In which the interaction between light and the material can 
be used for modulating the drug delivery system. In present 
study material should absorbs the light at desired wavelength 
and material uses energy from the absorb light. Example-
Gold nanoshell (a thin layer of gold surrounding a core of 
active nano particle). Embedding the nanoshells in a 
NIPAAm-co-AAM hydrogel formed the required composite 
material. When exposed to near-infrared light, nanoshells 
absorb the light and convert it to heat, raising the temperature 
of composite hydrogel above its LCST. That’s result in the 
increase rate release of the drug from matrix system34. 
Conclusion 
Sustained release formulations are not efficient in treating the 
diseases especially with chronological pathopysiology, for 
which, pulsatile drug delivery is effective to tackle diseases 
with non constant dosing therapies such as diabetes. 
Circardian rhythm of body is an important concept for 
understanding the optimum need of drug in the body in 
circardian disorders. It can be concluded that PDDS offer a 
solution for delivery of drugs exhibiting 
chronopharmacological behavior, extensive first-pass 
metabolism, necessity of night-time dosing, or absorption 
window in GIT. PDDS are smart and efficient dosage forms 
satisfying needs of patients and offering interesting options 
for intelligent life cycle management. But due to lack of 
manufacturing reproducibility, large process variables and 
multiple formulation steps, these are still in limited in 
market. But in future due to more advancement of 
technology, these hurdles will be overcome and a number of 
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patients will be greatly benefited by these systems. One 
major challenge will be to obtain a better understanding of 
the influence of the biological environment on the release 
performance of pulsatile delivery systems in order to develop 
simple systems based on approved excipients with a good in 
vitro-in vivo correlation. PDDS should ensure that the current 
high level of interest in this area would extend well in to 
future and result in the betterment of quality of life. 
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